Caprelsa (vandetanib) Tablets

ADVERSE REACTIONS

DRUG INTERACTIONS

Effect of CYP3A4 Inducers on CAPRELSA

Rifampicin, a strong CYP3A4 inducer, decreased vandetanib plasma concentrations. Avoid concomitant use of known strong CYP3A4 inducers during CAPRELSA therapy. Avoid concomitant use of St. John’s Wort because it can decrease vandetanib exposure unpredictably [Effect of CAPRELSA on OCT2 Transporter

CAPRELSA increased plasma concentrations of metforman that is transported by the organic cation transporter type 2 (OCT2). Use caution and closely monitor for toxicities when administering CAPRELSA with drugs that are transported by OCT2

Effect of CAPRELSA on Digoxin

CAPRELSA increased plasma concentrations of digoxin. Use caution and closely monitor for toxicities when administering CAPRELSA with digoxin

Drugs that Prolong the QT Interval

Avoid concomitant use of CAPRELSA with agents that may prolong the QT interval